SciBase receives additional Castle Biosciences order, expands collaboration
CSTL•Additional order supports atopic dermatitis study
SciBase received an additional order from Castle Biosciences to accelerate an ongoing atopic dermatitis relapse-prediction study.
Second study preparations included in collaboration
The order also covers preparations for a second clinical study under the 2025 collaboration and license agreement.
Deliveries are expected to start in Q4 2026.
